Therefore, a better standardization specific to people living with MS who demonstrate neuronal tissue loss (taking into consideration age, sex, and other inclusion criteria) requires reforming to validate serum NfL and CSF NfL over the course of disease progression. This evidence concerns the gene NEFL and myeloid sarcoma.